RGNX Stock Overview
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
REGENXBIO Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.04 |
52 Week High | US$28.80 |
52 Week Low | US$10.49 |
Beta | 1.26 |
11 Month Change | 19.63% |
3 Month Change | -22.70% |
1 Year Change | -26.33% |
33 Year Change | -58.35% |
5 Year Change | -66.89% |
Change since IPO | -57.18% |
Recent News & Updates
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Recent updates
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration
Oct 03Regenxbio: A Transformative Year
Sep 15Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
Aug 29Shareholder Returns
RGNX | US Biotechs | US Market | |
---|---|---|---|
7D | -9.0% | -3.0% | -2.8% |
1Y | -26.3% | 15.5% | 16.6% |
Return vs Industry: RGNX underperformed the US Biotechs industry which returned 15.5% over the past year.
Return vs Market: RGNX underperformed the US Market which returned 16.6% over the past year.
Price Volatility
RGNX volatility | |
---|---|
RGNX Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 14.5% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGNX's share price has been volatile over the past 3 months.
Volatility Over Time: RGNX's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 344 | Curran Simpson | www.regenxbio.com |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
REGENXBIO Inc. Fundamentals Summary
RGNX fundamental statistics | |
---|---|
Market cap | US$644.48m |
Earnings (TTM) | -US$241.08m |
Revenue (TTM) | US$89.04m |
7.2x
P/S Ratio-2.7x
P/E RatioIs RGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RGNX income statement (TTM) | |
---|---|
Revenue | US$89.04m |
Cost of Revenue | US$265.81m |
Gross Profit | -US$176.76m |
Other Expenses | US$64.31m |
Earnings | -US$241.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.88 |
Gross Margin | -198.51% |
Net Profit Margin | -270.74% |
Debt/Equity Ratio | 21.0% |
How did RGNX perform over the long term?
See historical performance and comparison